Panel Dives Into Non-Inferiority Margins
Executive Summary
Non-inferiority margins have been a tricky issue as antibiotic sponsors strive to show efficacy without large, lengthy and costly trials.
You may also be interested in...
Panel Supports Symptoms-Based Endpoint For Community-Acquired Bacterial Pneumonia
A means of standardizing what are subjective criteria must be developed, the advisory committee stressed to FDA Nov. 3.
Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends Sole Primary Endpoint
FDA's draft guidance for clinical trials of drugs for hospital-acquired or ventilator-associated bacterial pneumonia is strict, even compared with the draft guidance for community-acquired bacterial pneumonia.
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials